Dystrophin is a tumor suppressor in human cancers with myogenic programs
Yuexiang Wang(Shanghai Institute of Nutrition and Health), Jonathan A. Fletcher(Brigham and Women's Hospital), Matt van de Rijn(Stanford University), Tamás Ördög(Mayo Clinic), Adrián Mariño‐Enríquez(Harvard University Press), Richard Rodney Bennett(Brigham and Women's Hospital), Benjamin S. Fletcher(Brigham and Women's Hospital), Louis M. Kunkel(Howard Hughes Medical Institute), Mei‐Jun Zhu(Washington State University), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Zhizhan Gu(Brigham and Women's Hospital), Chandrajit P. Raut(Brigham and Women's Hospital), George D. Demetri(Unknown), Grant Eilers(Brigham and Women's Hospital), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Xiangqian Guo(Stanford Medicine), Jen‐Chieh Lee(National Taiwan University), Edward A. Fox(Dana-Farber Cancer Institute), Yiping Shen(Zhejiang Chinese Medical University), Joern Henze(Brigham and Women's Hospital)
Cited by 165
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Association between Microdeletion and Microduplication at 16p11.2 and Autism
|New England Journal of Medicine|2008|1.7k